Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

@article{Goujard2007InterruptionOA,
  title={Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.},
  author={C{\'e}cile Goujard and Fabienne Marcellin and Houria Hendel-Chavez and Marianne Burgard and Vincent Meiffr{\'e}dy and Alain Venet and Christine Rouzioux and Yacine Taoufik and Rapha{\"e}lle El Habib and Maria Beumont-Mauviel and J P Aboulker and Yves L{\'e}vy and J F Delfraissy},
  journal={AIDS research and human retroviruses},
  year={2007},
  volume={23 9},
  pages={1105-13}
}
HIV-specific T cell responses play a critical role in the control of infection. We evaluated the impact of immune-based interventions in patients first treated during primary HIV-1 infection (PHI). Forty-three patients were randomized within three groups, to receive either interleukin-2 (IL-2 group), or boosts of ALVAC-HIV (vCP1433) and LIPO-6T followed by… CONTINUE READING